apellis.com - APLS Profit before interest, taxes and amortization

Brandmark of Apellis (APLS)

Quarterly EBITDA reflects the financial trajectory of Apellis Pharmaceuticals (APLS), with the figure standing at 166.65. This trend is driven by the development of unique molecular therapies to combat rare vision pathologies and the active rollout of the first retinal atrophy treatment into US and European markets. Profit stability is supported by optimized distribution of ophthalmological products and the diversification of warehouse hubs.

Apellis Pharmaceuticals (APLS) Profit before payment of interest, taxes and amortization: for the period 11/23/2025 - 05/30/2026

Summary analytical data breakdowns for Apellis (APLS)

- market value and analyst target forecast:
Market Price Apellis Corp|APLS - Consensus Target
- issuer market value details:
Market Value Apellis Pharmaceuticals|APLS - Enterprise Value
- book capitalization data:
Net Asset Value per Share Apellis Pharmaceuticals|APLS - Company Book Value|Market Capitalization to Book Value apellis.com|APLS - Company Total Assets
- business debt structure and liquidity details:
Total Debt to Capital Apellis Pharmaceuticals|APLS - Long-Term Debt to Equity|Current Liabilities to Equity Apellis Pharmaceuticals, Inc.|APLS - Company Aggregate Debts|Debts to Book Value Apellis Pharmaceuticals|APLS - Company Long-Term Debt|Company Short-Term Debt Apellis Pharmaceuticals|Quick Liquidity apellis.com
- earnings and market multiples details:
APLS - Net Profit|Company Profit Forecast Apellis Pharmaceuticals|APLS - Price to Earnings Ratio|Market Cap to Projected Earnings apellis.com|APLS - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Apellis Pharmaceuticals|APLS - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months Apellis Pharmaceuticals|APLS - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months apellis.com|APLS - Earnings growth in current year|Earnings growth forecast for next year Apellis Pharmaceuticals
Summary company analytics:Apellis Pharmaceuticals
Original product of apellis.com

This indicator measures net cash flow from operating activities before deducting financial and tax expenses, allowing for a real-time assessment of the business's internal efficiency. By analyzing the annual EBITDA figure, an investor can see how the clinical research and manufacturing outsourcing strategy of Apellis Pharmaceuticals (APLS) impacts operating margins and the overall liquidity of the asset.

Competitors of Apellis Pharmaceuticals (APLS)

Alcon Corp (ALC) - Profit before interest, taxes and amortization|BLCO: Operating profit before deduction of amortization|Profit before interest, taxes and amortization glaukos.com|BLTE: Operating profit EBITDA|Profit before interest, taxes and amortization Ocular Therapeutix Inc (OCUL)|Profit before payment of interest, taxes and amortization Harrow Health|Viridian Corp (VRDN) - Operating income before deduction of amortization|Operating profit EBITDA LENZ|Operating profit EBITDA Oculis Holding AG (OCS)|Profit before payment of interest, taxes and amortization EyePoint Pharmaceuticals, Inc. EYPT|KOD (Kodiak Sciences Inc) - Profit before deduction of interest, taxes, depreciation and amortization|Aldeyra - Operating profit EBITDA|Profit before interest, taxes and amortization KALA BIO, Inc.|opusgtx.com (IRD) - Profit before payment of interest, taxes and amortization|OKYO (OKYO Pharma) - Profit before payment of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Adverum Biotechnologies Inc.|Profit before payment of interest, taxes and amortization OTLK|Operating profit EBITDA CLSD|Operating income before deduction of amortization novabay.com|Profit before payment of interest, taxes and amortization Kiora Pharmaceuticals, Inc. KPRX|Operating income before deduction of amortization Alimera Sciences Inc (ALIM)|EYEN: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization GHSI (Guardion Health Sciences, Inc.)|Ocuphire (OCUP) - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization OPT (Opthea Corp)